11931, Navarrete M, Rangel C, Espinosa-Garca J, Corchado JC
The goal is to help you set realistic expectations, understand what youre experiencing, and have more informed conversations with your care team
For instance: people with obesity are more likely to develop type 2 diabetes people with obesity are at an increased riskof developing Alzheimers later in life people with type 2 diabetes are also more likely to develop Alzheimers disease Alzheimers disease is associated with insulin resistance in the brain, with some scientists referring to Alzheimers as type 3 diabetes obesity, type 2 diabetes, and Alzheimers all involve inflammation, and GLP-1 agonists have an anti-inflammatory effect studies in animal models of dementiahave shown that GLP-1 agonists can protect rats brains from damage
This record proves valuable when discussing progress with healthcare providers
(Lausanne) 9 , 431 (2018)
The Endocrine Society's 2022 clinical practice guideline recommends GLP-1 receptor agonists as second-line therapy for type 2 diabetes after metformin, and most insurers align their prior authorization criteria with this sequencing